Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Finding opens avenues of research toward precision treatments to boost life expectancy for CF patients

Mutation of one gene is all it takes to get cystic fibrosis (CF), but disease severity depends on many other genes and proteins. For the first time, researchers at the UNC School of Medicine have identified genetic pathways - or clusters of genes - that play major roles in why one person with CF might never experience the worse kinds of symptoms while another person will battle severe airway infection for a lifetime.

23 Feb 2015

Possible cause of liver disease identified in adolescents with cystic fibrosis

A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis.

19 Feb 2015

World class drug discovery team launches new company to tackle chronic respiratory disease

Respiratory diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma represent a major unmet medical need and a significant health burden in both the developed and developing world.

16 Feb 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

Anthera Pharmaceuticals, Inc. today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA.

31 Dec 2014

PTC begins rolling NDA submission for Translarna to treat nmDMD

PTC Therapeutics, Inc. today announced that it has commenced a rolling submission of a New Drug Application to the United States Food and Drug Administration for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

23 Dec 2014

Ganciclovir drug resistance may occur more frequently in cystic fibrosis patients

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation.

22 Dec 2014

CF patients require close monitoring for resistance to ganciclovir after lung transplantation

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation.

18 Dec 2014

IRCM researchers uncover mechanism that regulates dopamine levels in the brain

Researchers in Montréal led by Jacques Drouin, D.Sc., uncovered a mechanism regulating dopamine levels in the brain by working on a mouse model of late onset Parkinson's disease.

12 Dec 2014

Chemical chaperone: A new therapeutic option for epilepsy

Researchers found out that the conformational defect in a specific protein causes Autosomal Dominant Lateral Temporal Lobe Epilepsy (ADLTE) which is a form of familial epilepsy. They showed that treatment with chemical corrector called "chemical chaperone" ameliorates increased seizure susceptibility in a mouse model of human epilepsy by correcting the conformational defect.

10 Dec 2014

Drug proves effective at inhibiting growth of drug-resistant bacteria

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes.

10 Dec 2014

Study sheds new light on well-known mechanism required for immune response

A new study published in the scientific journal Proceedings of the National Academy of Sciences of the United States of America sheds new light on a well-known mechanism required for the immune response. Researchers at the IRCM, led by Tarik Möröy, PhD, identified a protein that controls the activity of the p53 tumour suppressor protein known as the "guardian of the genome".

6 Dec 2014

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

On Tuesday, the FDA granted final approval of PulmoFlow, Inc.'s New Drug Application for Kitabis Pak – a co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer. This is the first nebulized drug and device combination to be approved for patients with cystic fibrosis.

3 Dec 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

24 Nov 2014

Unique ability helps prolific bacterium to afflict humans, animals and even plants

New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism -- a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment.

23 Nov 2014

TSRI study examines body’s own response against chronic protein misfolding

“Protein misfolding” diseases such as cystic fibrosis and Alzheimer’s may be seriously exacerbated by the body’s own response against that misfolding, according to a new study led by scientists at The Scripps Research Institute.

20 Nov 2014

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014.

16 Nov 2014

Salivary mucins protect teeth from cariogenic bacterium

Salivary mucins, key components of mucus, actively protect the teeth from the cariogenic bacterium, Streptococcus mutans, according to research published ahead of print in Applied and Environmental Microbiology. The research suggests that bolstering native defenses might be a better way to fight dental caries than relying on exogenous materials, such as sealants and fluoride treatment, says first author Erica Shapiro Frenkel, of Harvard University, Cambridge, MA.

11 Nov 2014

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Murdoch University researchers from the Centre for Comparative Genomics have received almost $800,000 in funding from the National Health and Medical Research Council to develop genetic drugs to treat rare diseases.

6 Nov 2014

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Finding opens avenues of research toward precision treatments to boost life expectancy for CF patients

Possible cause of liver disease identified in adolescents with cystic fibrosis

World class drug discovery team launches new company to tackle chronic respiratory disease

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

PTC begins rolling NDA submission for Translarna to treat nmDMD

Ganciclovir drug resistance may occur more frequently in cystic fibrosis patients

CF patients require close monitoring for resistance to ganciclovir after lung transplantation

IRCM researchers uncover mechanism that regulates dopamine levels in the brain

Chemical chaperone: A new therapeutic option for epilepsy

Drug proves effective at inhibiting growth of drug-resistant bacteria

Study sheds new light on well-known mechanism required for immune response

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Unique ability helps prolific bacterium to afflict humans, animals and even plants

TSRI study examines body’s own response against chronic protein misfolding

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Salivary mucins protect teeth from cariogenic bacterium

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in